August 1 is #WorldLungCancerDay. The American Cancer Society predicts that there will be more than 100,000 deaths from #LungCancer this year. When lung cancer is found at an earlier stage before it spreads, it’s more likely to be treated successfully. That’s why it’s so important that more individuals get screened – even if they may not be experiencing symptoms. At On Target, we’re committed to helping patients and doctors fight this disease. Our targeted intraoperative molecular imaging agent helps surgeons visualize early-stage lung cancer, remove more cancer during surgery, and contributes to a world with better #LungHealth. #WLCD24 To learn more about our intraoperative molecular imaging agent and risk related information, please visit https://bit.ly/3yr0tVN
On Target Laboratories’ Post
More Relevant Posts
-
𝐃𝐚𝐲 𝟓 𝐨𝐟 𝐁𝐫𝐞𝐚𝐬𝐭 𝐜𝐚𝐧𝐜𝐞𝐫! Today, we’re diving into the crucial treatment options available for breast cancer. From surgery to radiation therapy and the innovative use of the perfusor during chemotherapy, each treatment is a tailored approach that empowers patients in their fight against cancer. Understanding these options is vital for making informed decisions alongside your healthcare team. This knowledge can be a powerful ally on the journey to recovery. We hope this series has equipped you with valuable insights and encourages ongoing conversations about breast cancer awareness. #zuvius #cancer #cancerawareness #fightcancer #beatcancer Nimishh Thakkar; Shailesh Shetty; Alka Chavan; Swapnil Kamble
To view or add a comment, sign in
-
Laparoscopic cholecystectomy frequently reveals gallbladder cancers (GBCs), often previously undiagnosed. Given the poor prognosis of GBC, understanding factors influencing outcomes is vital. A systematic review by Dr. Kavin Sugumar explores the prognostic significance of biliary spillage (BS)—the accidental leakage of bile during surgery—finding that BS might worsen survival rates by spreading cancer cells. These insights could reshape surgical practices and improve postoperative management for GBC patients. #TulaneResearch #Cancer #Oncology Read the paper in the comments! Image: Results from individual studies and aggregated data suggest bile spillage is associated with decreased overall survival.
To view or add a comment, sign in
-
Rutgers Cancer Institute Oncologist Spotlight ⭐ Haejin In, MD MPH MBA's clinical expertise and research interests are dedicated to improving the quality of care in the outcomes of gastrointestinal (GI) cancer patients, including stomach, esophageal, pancreas and peritoneal surface malignancies. Clinically, her focus has been in providing state-of-the-art, minimally invasive surgeries, particularity for #StomachCancer, while adhering to the most rigorous of oncologic surgery principles to provide those with cancer the greatest chance of cure. Learn more about Dr. In https://lnkd.in/e6mFKiuZ RWJBarnabas Health #StomachCancerAwareness #StomachCancerAwarenessMonth #Cancer
To view or add a comment, sign in
-
Multidisciplinary Treatment Approach for Rectal Cancer – Discussion with Drs. Deb Schrag & Krishan Jethwa The discussion revolves around the findings of the Prospect study, which explored the possibility of avoiding radiation in select rectal cancer patients to minimize long-term side effects. The study showed that outcomes were comparable between traditional treatment methods and the selective approach, with a quality-of-life advantage for the latter. The hosts and guests also touch upon the evolving paradigm of radiation therapy, the importance of MSI high status testing, and the considerations for omitting surgery in certain cases. They emphasize the need for a multidisciplinary approach and tailoring treatment based on individual patient characteristics. Overall, the episode highlights the significance of personalized treatment strategies in managing locally advanced rectal cancer and the importance of staying abreast of the latest research and advancements in the field. See Live Session: https://lnkd.in/dzEBEsyc Learn more: https://lnkd.in/d-5AhY83 #cancertreatment #oncologypodcast #oncologistsnearme
To view or add a comment, sign in
-
The ADELE study is a randomised phase II trial designed to improve outcomes for women with high-risk endometrial cancer. Under the leadership of Prof Linda Mileshkin and Dr Yeh Chen Lee, the study examines the impact of adjuvant tislelizumab in combination with chemotherapy following post-operative pelvic chemoradiation. Endometrial cancer is the most prevalent and fastest-growing gynecological cancer in Australia and New Zealand. The standard initial treatment is a hysterectomy, but many women with advanced disease or high-risk histology are not cured by surgery alone. The ADELE trial seeks to address this challenge by providing robust evidence for a new treatment plan that improves patient outcomes. #UCAM #UterineCancerAwarenessMonth Read more: https://lnkd.in/gzV6eJSz
To view or add a comment, sign in
-
For 70 years we have been taking prostate glands out of men in an attempt to “cure” prostate cancer. For about the same length of time we have been sticking needles in prostate glands in a scavenger hunt looking for cancer cells. These approaches seem logical and have become the standard of care. But there is a problem, the current approach to diagnosing and treating prostate cancer has not been demonstrated to actually cure cancer, or even help men live longer. On the other hand biopsies, surgery and radiation cause harm. How did we get stuck in this place, and is there anything we can do about it? Tune in to listen 🔊 https://vist.ly/yi42 #podcasts #Dr.StephenPetteruti #Prostatecancer #menshealth
To view or add a comment, sign in
-
In the latest episode of "The Immuno-Oncology Curve," Dr. Steven O'Day talks with Agenus colleagues Dr. Joseph Grossman and Dr. Benny Johnson. Learn why they left the practice of medicine to fight cancer on a different front. Recently back from this year’s #ASCO GI Cancers Symposium, the doctors discuss the perplexing rise of early-onset cancers, the ongoing challenge of diversity in cancer clinical trials, the use of circulating tumor DNA (ctDNA) as a biomarker, and the overall potential of I-O to reduce dependence on chemotherapy and surgery. Listen and subscribe at: https://bit.ly/4bNIAzJ
To view or add a comment, sign in
-
It’s officially Men’s Health Month and the start to #ASCRS24. Colorectal cancer is third most common cancer among men and women in the U.S.* Come visit us at booth #420 to learn more about the utility of the 1788 Platform, SPY-PHI and Illuminated Instruments in colorectal surgery. #MensHealthMonth #ColorectalCancer #ColorectalSurgery #1788Platform *Colorectal cancer statistics: How common is colorectal cancer?. Colorectal Cancer Statistics | How Common Is Colorectal Cancer? | American Cancer Society. (n.d.). https://lnkd.in/gRvPJzKt
To view or add a comment, sign in
-
October is Liver Cancer Awareness Month! To mark this occasion, we are happy to share insights from Dr. Roberto Luigi Cazzato, Chairperson of CIRSE’s Research Committee and Coordinating Investigator of BOREALIS, the new CIRSE-sponsored registry in bone metastases. “Interventional radiology is a key player in the management of liver cancers with treatments such as ablation and radioembolization that are changing treatment paradigms for patients with liver cancer. In particular, radioembolization has added new therapeutic alternatives to patients with locally advanced liver tumours and percutaneous ablation has shown results that may be even better than those obtained by surgery (better local tumour control, shorter hospital stays and less complications), at least for small-sized CRLM (< 3 cm), as highlighted by the COLLISION trial. Next Research is highly involved in these two fields with multiple studies such as CIRT and CIEMAR.” Explore our studies and publications 👉 https://lnkd.in/eiUmbYgA #LiverCancerAwarenessMonth #InterventionalRadiology #Research #LiverCancer
To view or add a comment, sign in
-
Hello LinkedIn community Brain cancer is a serious condition characterized by the uncontrolled growth of cells within the brain. It can originate in the brain (primary brain cancer) or spread from other parts of the body (secondary, or metastatic, brain cancer). Primary brain tumors can be benign (non-cancerous) or malignant (cancerous), with gliomas and meningiomas being among the most common types. Symptoms of brain cancer vary depending on the tumor's size, location, and rate of growth and may include headaches, seizures, cognitive or personality changes, and motor skill impairments. Diagnosis typically involves imaging studies such as MRI or CT scans, and treatment options include surgery, radiation therapy, and chemotherapy. Advances in medical research are continuously improving the understanding and management of brain cancer, offering hope for better outcomes for patients. #snsinstitutions #snsdesignthinker #designthinking
To view or add a comment, sign in
3,540 followers